22 compounds, the same columns for all of them — including the ones we do not stock, because a comparison that only contains our catalogue is a price list.
| Property | BPC-157Body Protection Compound-157 | TB-500Thymosin Beta-4 fragment | GHK-CuCopper peptide |
|---|---|---|---|
| Class | Synthetic pentadecapeptide | Synthetic peptide fragment | Copper-binding tripeptide |
| Target | No single characterised receptor | G-actin (sequestration, not a receptor) | Copper transport / gene expression |
| Structure | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 residues) | Gly-His-Lys (copper complex) |
| Molecular weight | 1419.53 Da | ~4963.4 Da | ~403.92 Da |
| Formula | C₆₂H₉₈N₁₆O₂₂ | C₂₁₂H₃₅₀N₅₆O₇₈S | C₁₄H₂₄CuN₆O₄ |
| CAS number | 137525-51-0 | 77591-33-4 | 89030-95-5 |
| Half-life | Not established | Not established | Not established |
| Human evidence | No published human trials | No published human trials | Early / small human studies |
| Studied in |
|
|
|
| Notes | — | TB-500 is not Thymosin Beta-4 itself — it is a fragment. The two are routinely conflated. | — |
| Availability | In catalogue$89.99 | In catalogue$84.99 | In catalogue$94.99 |
Molecular data from the certificate of analysis for each batch. Half-life and evidence level reflect the published literature cited in our research articles. Research use only.
The most useful column is the least flattering one. Several widely discussed research peptides have no published human trials at all, and the tool says so rather than filling the cell with mechanism language.
Reference data for laboratory research. Nothing here describes an outcome, a protocol or a therapeutic use. Molecular figures come from the certificate of analysis for each batch; pharmacology reflects the literature cited in our research articles.